Erasca Inc share price logo

Erasca Inc

NASDAQ: ERAS

Mid Cap

$9.89

-9.25

(-48.33%)

as on

Erasca Inc Stock Performance

as on April 29, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $8.70
    $10.57
    downward going graph

    12.03%

    Downside

    6.88%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.06
    $24.28
    downward going graph

    89.28%

    Downside

    145.50%

    Upside

    downward going graph

Erasca Inc share price movements today

Previous Close
$19.15
Open
$10.56
Volume
64.5M
Day's Low - High
$8.70 - $10.57
52 Week Low - High
$1.06 - $24.28

Erasca Inc Historical Returns

1 Month Return
+ 27.92 %
3 Month Return
+ 89.04 %
1 Year Return
+ 1267.86 %
3 Year Return
+ 593.84 %
5 Year Return
0 %

Erasca Inc Stock Fundamentals & Key Indicators

Check Erasca Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.7B

EPS (TTM)

-0.5677

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-128.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-33.27%

Erasca Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Erasca Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Erasca Inc image
Erasca Inc
BUY$6.7BNANA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$40.8B114.94%131.78.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.5B99.55%28.132.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.4BNA121.785.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.0B52.62%17.9531.41%

Stock Returns calculator for Erasca Inc Stock including INR - Dollar returns

The Erasca Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Erasca Inc investment value today

Current value as on today

₹7,84,050

Returns

₹6,84,050

(+684.05%)

Returns from Erasca Inc Stock

₹6,06,429 (+606.43%)

Dollar Impact

₹77,621 (+77.62%)

Analyst Recommendation on Erasca Inc Stock

Based on 14 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 14 analysts, 85.71% of analysts recommend a 'BUY' rating for Erasca Inc. Average target price of $18.1

Erasca Inc Share Price Target

Get share price movements and forecasts by analysts on Erasca Inc.

What analysts predicted

45.36%UPSIDE

Target Price

$18.1

Current Price

$9.89

Analyzed by

14 Analysts

Target

$18.10

Erasca Inc target price $18.1, a slight upside of 45.36% compared to current price of $9.89. According to 14 analysts rating.

Erasca Inc Stock’s Investor Sentiment and Interest

Investment in Erasca Inc Shares on INDmoney has grown by 120.58% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:120.58% versus previous 30 day period

Search interest for Erasca Inc Stock has increased by 50% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:50% versus previous 30 day period

Erasca Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
5
-
-
-
4
-
-
-
-
Gross Profit
0
0
0
-1
0
0
0
0
-
0
Operating Income
-34
-33
-38
-67
-37
-35
-35
-38
-34
-32
EBITDA
-33
-28
-37
-44
-36
-31
-34
-29
-29
-31
Interest Expense
-
3
-
-
-
-
-
-
-
-
Depreciation
0
0
0
1
0
0
0
0
0
0
Income Before Tax
-30
-29
-35
-63
-31
-32
-30
-33
-30
-29
Income Tax Expense
-5
13
0
-
-
0
-
-
-
-
Net Income
-30
-29
-35
-63
-31
-32
-30
-33
-30
-29
Net Profit Margin
0.00%
-532.28%
0.00%
0.00%
0.00%
-768.16%
0.00%
0.00%
0.00%
0.00%

Erasca Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
Gross Profit
0
0
0
-2
-3
-3
-3
Operating Income
-13
-109
-124
-247
-141
-179
-131
EBITDA
-12
-36
-121
-240
-121
-153
-128
Interest Expense
-
0
55
201
-
-
-
Depreciation
0
0
0
2
3
3
3
Income Before Tax
-12
-101
-122
-242
-125
-161
-124
Income Tax Expense
-1
71
27
-4
-
-
-
Net Income
-12
-101
-122
-242
-125
-161
-124
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Erasca Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-29
-35
-63
-31
-32
-30
-33
-30
-29
Operating Cash Flow
-24
-33
-29
-22
-24
-31
-20
-21
-21
Investing Cash Flow
4
9
-86
-102
22
34
15
25
24
Financing Cash Flow
0
6
211
21
0
0
0
0
0
Change in Cash
-19
-16
96
-103
-1
2
-4
4
3

Erasca Inc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-101
-122
-242
-125
-161
-124
Operating Cash Flow
-32
-79
-103
-101
-109
-95
Investing Cash Flow
-71
-64
-71
-91
-156
100
Financing Cash Flow
139
439
98
1
240
1
Change in Cash
36
295
-76
-191
-25
6

Global Institutional Holdings in Erasca Inc

Funds
Holdings
State Street Corp
1.3%
Goldman Sachs Group Inc
0.64%
Suvretta Capital Management, LLC
4.67%
Logos Global Management LP
4.18%
Millennium Management LLC
0.94%
See all

Erasca Inc News & Key Events

  • img

    Today's Timeline - 28 April

    Tue, 03:27 PM

    -

    Erasca shares plummet nearly 50% after patient death in ERAS-0015 trial, despite promising early clinical data.

Insights on Erasca Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ERAS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ERAS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, ERAS stock has moved up by 684.8%

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
OrganisationErasca Inc
Headquarters3115 Merryfield Row, San Diego, CA, United States, 92121
IndustryBiotechnology
CEODr. Jonathan E. Lim M.D.
E-voting on sharesClick here to vote

Key Management of Erasca Inc

Name

Title

Dr. Lisa Tesvich-Bonora Ph.D.

Chief People Officer

Mr. Brian L. Baker CPA, M.S.

Senior Vice President of Finance

Dr. David M. Chacko M.D.

CFO & Chief Business Officer

Dr. Shannon R. Morris M.D., Ph.D.

Chief Medical Officer

Dr. Nik Chetwyn Ph.D.

Chief Operating Officer

Ms. Chandra D. Lovejoy M.S.

Chief Regulatory Affairs Officer

Ms. Minli Xie Ph.D.

Senior Vice President of Pharmaceutical Development & Operations

Dr. Jonathan E. Lim M.D.

Co-Founder, Chairman & CEO

Dr. Robert Shoemaker Ph.D.

Chief Scientific Officer

Mr. Ebun S. Garner Esq., J.D.

Chief Legal Officer & Corporate Secretary

FAQs

What is Erasca Inc share price today?

Erasca Inc share price today is $9.89 as on at the close of the market. Erasca Inc share today touched a day high of $10.57 and a low of $8.7.

What is the 52 week high and 52 week low for Erasca Inc share?

Erasca Inc share touched a 52 week high of $24.28 on and a 52 week low of $1.06 on . Erasca Inc stock price today i.e. is closed at $9.89,which is 59.27% down from its 52 week high and 833.02% up from its 52 week low.

What is Erasca Inc's market capitalisation today?

Erasca Inc market capitalisation is $0.01T as on .

How to invest in Erasca Inc Stock (ERAS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Erasca Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Erasca Inc Shares that will get you 0.1517 shares as per Erasca Inc share price of $9.89 per share as on April 29, 2026 at 1:29 am IST.

What is the minimum amount required to buy Erasca Inc Stock (ERAS) from India?

Indian investors can start investing in Erasca Inc (ERAS) shares with as little as ₹94.52 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹945.20 in Erasca Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Erasca Inc share’s latest price of $9.89 as on April 29, 2026 at 1:29 am IST, you will get 1.0111 shares of Erasca Inc. Learn more about fractional shares .